Skip to Main Content

Paper Details

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
Neuro Oncol
36
2017
GBM, GBM PDX, GBM patient-derived xenografts, Glioblastoma, KrasG12D, MAPK, MEK, PDX, PI3K, Pten, RTK, glioblastoma, immortalized astrocytes, mitogen-activated protein kinase, mitogen-activated protein kinase kinase, mouse, murine, mutant murine astrocytes, patient, phosphoinositide 3-kinase, primary brain tumor, receptor tyrosine kinase, tumor, tumor samples, tyrosine
Author NameAffiliation
Ryan E BashLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Ryan E BashLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Laura E HerringLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Jeremy M SimonLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Erik P SulmanLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Erik P SulmanLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Jann N SarkariaLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Carey K AndersLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Michael E BerensLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Gary L JohnsonLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Christopher Ryan MillerLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
Christopher Ryan MillerLineberger Comprehensive Cancer Center, Carolina Institute for Developmental Disabilities, University of North Carolina (UNC) School of Medicine, Mayo Clinic, University of Texas M.D. Anderson Cancer Center
  • 1 - 12

Datasets

Release 1.2